LPGAT1 Inhibitors
LPGAT1 inhibitors are a diverse group of compounds that attenuate the activity of LPGAT1 by modulating various biochemical pathways related to lipid metabolism. PI3K inhibitors such as LY 294002 and Wortmannin effectively downregulate the PI3K/Akt signaling pathway, which is instrumental in regulating phospholipid synthesis and turnover. The reduced activity within this pathway curtails the generation of lipid substrates essential for LPGAT1's enzymatic function, thereby leading to its functional inhibition. Similarly, the fatty acid synthase inhibitors Cerulenin and C75 restrict the biosynthesis of new fatty acids, diminishing the availability of lysophospholipid substrates for LPGAT1 and consequently decreasing its activity. Inhibition of Akt by compounds like Triciribine and Perifosine further contributes to the reduction of lipid metabolism and substrate availability for LPGAT1, suppressing its functional expression.
Additionally, the MEK inhibitor PD 98059 impedes the MAPK/ERK pathway, potentially altering the cellular demand and remodeling of phospholipids, which in turn can affect LPGAT1 function. The mTOR inhibitor Rapamycin and the lipase inhibitor THL both result in a lowered synthesis and turnover of lipids, leading to a deficiency in lysophospholipid substrates required by LPGAT1. Simvastatin, by inhibiting cholesterol synthesis, affects membrane lipid composition, which could indirectly influence LPGAT1 activity. Betulinic Acid's inhibition of SREBPs reduces the expression of lipid biosynthesis genes, subsequently leading to a decrease in substrate availability for LPGAT1. Lastly, Imatinib, a tyrosine kinase inhibitor, may impact cellular signal transduction pathways involved in lipid metabolism, thereby potentially reducing the availability of substrates for LPGAT1 and diminishing its enzymatic activity. Each of these inhibitors targets specific aspects of lipid metabolism and signaling, converging on the reduction of LPGAT1 activity through decreased substrate availability and altered lipid metabolic processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, LY 294002 leads to a downregulation of the PI3K/Akt signaling pathway. Given that LPGAT1 activity is associated with phospholipid remodeling, which can be influenced by PI3K activity, inhibition of PI3K by LY 294002 diminishes LPGAT1 functional expression by reducing the supply of lipid substrates required for its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that impairs the PI3K/Akt pathway. The inhibition of this pathway results in decreased phospholipid synthesis and remodeling, indirectly leading to diminished LPGAT1 activity due to a lack of available substrates. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
As a fatty acid synthase inhibitor, Cerulenin effectively reduces the synthesis of new fatty acids, which are precursors for the synthesis of lysophospholipids. LPGAT1, which acts on lysophospholipids, would have reduced activity as a consequence of the diminished availability of these substrates. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits Akt, a downstream effector of PI3K. By inhibiting Akt, Triciribine indirectly leads to reduced lipid metabolism and potentially less substrate availability for LPGAT1, thus diminishing its activity. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an alkylphospholipid that inhibits Akt. By diminishing Akt signaling, perifosine indirectly reduces LPGAT1 activity through decreased phospholipid turnover and reduced substrate availability for LPGAT1. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $72.00 $206.00 $290.00 | 9 | |
C75 is a synthetic fatty acid synthase inhibitor that would lead to decreased fatty acid availability. This reduction in fatty acid levels indirectly diminishes the activity of LPGAT1 by limiting the synthesis of lysophospholipids, which are LPGAT1's substrates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, PD 98059 interferes with the MAPK/ERK pathway which is involved in cellular growth and differentiation, including lipid metabolism. This can indirectly affect LPGAT1 function by altering the cellular demand and remodeling of phospholipids. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin can downregulate the PI3K/Akt/mTOR pathway, leading to reduced lipid synthesis and turnover. This indirectly causes a decrease in LPGAT1 activity due to lower levels of lysophospholipid substrates. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
As an HMG-CoA reductase inhibitor, Simvastatin decreases cholesterol synthesis. Cholesterol is an integral part of membrane lipids, and its reduced synthesis can influence the overall lipid composition, potentially diminishing LPGAT1 activity due to altered membrane dynamics. | ||||||
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
THL is a lipase inhibitor that reduces the breakdown of fats, ultimately leading to decreased fatty acid availability. This reduced availability could indirectly lead to diminished LPGAT1 activity by limiting the production of lysophospholipids. | ||||||